Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Trellus Health PLC (LSE:TRLS) has released its audited financial statements for the year ending December 31, 2024, revealing notable progress on both operational and strategic fronts. Among the year’s achievements were pivotal agreements with a major U.S. national health insurer and several pharmaceutical partners, underlining the company’s commitment to expanding its footprint in commercial partnerships and clinical research initiatives.
The company reported an adjusted EBITDA loss of $7.2 million for the year but managed to extend its financial runway through October 2025. Trellus is actively pursuing additional financing to support operations beyond that timeframe, with funding needs presenting a key area of focus.
A major milestone during the year was the launch of a pilot initiative with Johnson & Johnson, aimed at assisting individuals living with Inflammatory Bowel Disease (IBD). This pilot highlights the growing applicability of Trellus Health’s flagship solution, the Trellus Elevate® platform, which integrates behavioral and physical health care to improve outcomes for chronic disease patients.
Despite these advancements, the company acknowledged that the necessity for further capital before October 2025 introduces significant uncertainty regarding its future operations.
About Trellus Health PLC
Trellus Health PLC is a health tech company that delivers science-backed, data-driven solutions to enhance the management of chronic illnesses. Its core offering, the Trellus Elevate® platform, addresses the interconnection between mental and physical health challenges in chronic conditions, with a strong focus on gastrointestinal diseases such as IBD. The platform is designed to improve patient resilience, drive greater treatment adherence, and lower healthcare costs through personalized digital support and care coordination.
